Danielle C O Coutinho1, Gustavo Monnerat-Cahli2, Anderson J Ferreira3, Emiliano Medei2. 1. Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Av. Antônio Carlos, 6627-31.270-901, Belo Horizonte, MG, Brazil. 2. Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Ilha do Fundão, 21.949-000, Rio de Janeiro, Brazil. 3. Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Av. Antônio Carlos, 6627-31.270-901, Belo Horizonte, MG, Brazil anderson@icb.ufmg.br.
Abstract
AIMS: Diabetic patients present a high level of cardiac arrhythmias and risk of cardiac sudden death. The renin-angiotensin system (RAS) plays a key role in diabetes and cardiac diseases. The present study aimed to evaluate whether an angiotensin-converting enzyme 2 (ACE2) activator, diminazene aceturate (DIZE), could improve the streptozotocin (STZ)-induced electrical changes in ventricular repolarization in hyperglycaemic rats. METHODS AND RESULTS: Hyperglycaemia was induced in Wistar male rats with STZ (60 mg/kg/iv). After 4 weeks of STZ injection, rats were daily treated with saline (control) or DIZE (1 mg/kg/gavage) for four consecutive weeks. The cardiac electrical function was evaluated in vivo by electrocardiogram and in vitro by cardiac action potential records in different pacing frequencies. Treatment with DIZE was not able to reverse hyperglycaemia nor body weight loss. However, DIZE reversed hyperglycaemia-induced cardiac electrical changes in ventricular repolarization. Specifically, animals treated with DIZE showed shorter QT and QTc intervals. In addition, ACE2 activation was capable to shorten the cardiac action potential and also reverse the arrhythmic markers. Diminazene aceturate treatment did not induce arrhythmic events in normal, as well as in hyperglycaemic animals. CONCLUSION: Our data indicate that activation of ACE2 has a beneficial effect in hyperglycaemic rats, improving the cardiac electrical function. Thus, DIZE represents a promising new therapeutic agent to treat hyperglycaemia-induced cardiac electrical changes in ventricular repolarization. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Diabeticpatients present a high level of cardiac arrhythmias and risk of cardiac sudden death. The renin-angiotensin system (RAS) plays a key role in diabetes and cardiac diseases. The present study aimed to evaluate whether an angiotensin-converting enzyme 2 (ACE2) activator, diminazene aceturate (DIZE), could improve the streptozotocin (STZ)-induced electrical changes in ventricular repolarization in hyperglycaemic rats. METHODS AND RESULTS: Hyperglycaemia was induced in Wistar male rats with STZ (60 mg/kg/iv). After 4 weeks of STZ injection, rats were daily treated with saline (control) or DIZE (1 mg/kg/gavage) for four consecutive weeks. The cardiac electrical function was evaluated in vivo by electrocardiogram and in vitro by cardiac action potential records in different pacing frequencies. Treatment with DIZE was not able to reverse hyperglycaemia nor body weight loss. However, DIZE reversed hyperglycaemia-induced cardiac electrical changes in ventricular repolarization. Specifically, animals treated with DIZE showed shorter QT and QTc intervals. In addition, ACE2 activation was capable to shorten the cardiac action potential and also reverse the arrhythmic markers. Diminazene aceturate treatment did not induce arrhythmic events in normal, as well as in hyperglycaemic animals. CONCLUSION: Our data indicate that activation of ACE2 has a beneficial effect in hyperglycaemic rats, improving the cardiac electrical function. Thus, DIZE represents a promising new therapeutic agent to treat hyperglycaemia-induced cardiac electrical changes in ventricular repolarization. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Gustavo Monnerat; Micaela L Alarcón; Luiz R Vasconcellos; Camila Hochman-Mendez; Guilherme Brasil; Rosana A Bassani; Oscar Casis; Daniela Malan; Leonardo H Travassos; Marisa Sepúlveda; Juan Ignacio Burgos; Martin Vila-Petroff; Fabiano F Dutra; Marcelo T Bozza; Claudia N Paiva; Adriana Bastos Carvalho; Adriana Bonomo; Bernd K Fleischmann; Antonio Carlos Campos de Carvalho; Emiliano Medei Journal: Nat Commun Date: 2016-11-24 Impact factor: 14.919
Authors: Vitória Santório de São José; Gustavo Monnerat; Barbara Guerra; Bruno Dias Paredes; Tais Hanae Kasai-Brunswick; Antonio Carlos Campos de Carvalho; Emiliano Medei Journal: Arq Bras Cardiol Date: 2017-12 Impact factor: 2.000
Authors: Jorg Taubel; Dominic Pimenta; Samuel Thomas Cole; Claus Graff; Jørgen K Kanters; A John Camm Journal: Clin Res Cardiol Date: 2022-05-21 Impact factor: 6.138
Authors: Zachi I Attia; Suraj Kapa; Jennifer Dugan; Naveen Pereira; Peter A Noseworthy; Francisco Lopez Jimenez; Jessica Cruz; Rickey E Carter; Daniel C DeSimone; John Signorino; John Halamka; Nikhita R Chennaiah Gari; Raja Sekhar Madathala; Pyotr G Platonov; Fahad Gul; Stefan P Janssens; Sanjiv Narayan; Gaurav A Upadhyay; Francis J Alenghat; Marc K Lahiri; Karl Dujardin; Melody Hermel; Paari Dominic; Karam Turk-Adawi; Nidal Asaad; Anneli Svensson; Francisco Fernandez-Aviles; Darryl D Esakof; Jozef Bartunek; Amit Noheria; Arun R Sridhar; Gaetano A Lanza; Kevin Cohoon; Deepak Padmanabhan; Jose Alberto Pardo Gutierrez; Gianfranco Sinagra; Marco Merlo; Domenico Zagari; Brenda D Rodriguez Escenaro; Dev B Pahlajani; Goran Loncar; Vladan Vukomanovic; Henrik K Jensen; Michael E Farkouh; Thomas F Luescher; Carolyn Lam Su Ping; Nicholas S Peters; Paul A Friedman Journal: Mayo Clin Proc Date: 2021-08 Impact factor: 7.616